Baxter International Inc.'s (NYSE: BAX) stock soared 8.24% in the intraday trading session on Thursday, following the company's impressive fourth-quarter 2024 results and a robust outlook for 2025.
The medical products company reported better-than-expected earnings for the fourth quarter, with adjusted earnings per share of $0.77 surpassing the consensus estimate of $0.52. Revenue of $2.75 billion also beat analysts' expectations of $2.67 billion, driven by solid demand across its product portfolio.
Baxter's strong performance has boosted investor confidence, as the company provided an optimistic outlook for 2025. The company expects sales growth from continuing operations of 5% to 6% on a reported basis, and 4% to 5% on an operational basis. Additionally, Baxter projected adjusted earnings from continuing operations, before special items, to range between $2.45 and $2.55 per diluted share, exceeding the consensus estimate of $2.47.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。